menu ☰
menu ˟

Watching a Procedure Evolve Sequential Findings From the TVT Registry ∗

29 Dec 2015

Transcatheter aortic valve replacement (TAVR) has rapidly expanded in the United States and worldwide. The approval of the first 2 TAVR prostheses in the United States is based on data from randomized trials showing survival rates superior to conservative medical therapy in nonoperable patients (1,2) and comparable or superior to surgical aortic valve replacement (SAVR) for patients at high surgical risk (3,4). Data from these trials have now been extended to 5-year outcomes for the PARTNER (Placement of Aortic Transcatheter Valves) trial and 2-year outcomes for the CoreValve trial, and continue to confirm the initial findings (58). These trials represent some of the most robust clinical investigations available in the field of valvular heart disease. However, it has long been recognized that observations from clinical trials are not necessarily reflective of outcomes and practices in the broader population, often referred to as “the real world” (9).

Click here to view the full article which appeared in Journal of the American College of Cardiology Current Issue